Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Dalavaye:2022:10.1080/17474124.2022.2161046,
author = {Dalavaye, N and Erridge, S and Nicholas, M and Pillai, M and Bapir, L and Holvey, C and Coomber, R and Rucker, JJ and Hoare, J and Sodergren, MH},
doi = {10.1080/17474124.2022.2161046},
journal = {Expert Review of Gastroenterology and Hepatology},
pages = {85--98},
title = {The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry},
url = {http://dx.doi.org/10.1080/17474124.2022.2161046},
volume = {17},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivesCannabis-based medicinal products (CBMPs) have shown promising preclinical activity in inflammatory bowel disease (IBD). However, clinical trials have not demonstrated effects on inflammation. This study aims to analyze changes in health-related quality of life (HRQoL) and adverse events in IBD patients prescribed CBMPs.MethodsA case series from the UK Medical Cannabis Registry was performed. Primary outcomes included changes from baseline in the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), Generalized Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L Index score at 1 and 3 months. Statistical significance was defined using p < 0.050.ResultsSeventy-six patients with Crohn’s disease (n = 51; 67.11%) and ulcerative colitis (n = 25; 32.89%) were included. The median baseline SIBDQ score improved at 1 and 3 months. EQ-5D-5L index values, GAD-7, and SQS also improved after 3 months (p < 0.050). Sixteen (21.05%) patients reported adverse events with the majority being classified as mild to moderate in severity.ConclusionPatients treated with CBMPs for refractory symptoms of Crohn’s disease and ulcerative colitis demonstrated a short-term improvement in IBD-specific and general HRQoL. Prior cannabis consumers reported greater improvement compared to cannabis-naïve individuals.
AU  - Dalavaye,N
AU  - Erridge,S
AU  - Nicholas,M
AU  - Pillai,M
AU  - Bapir,L
AU  - Holvey,C
AU  - Coomber,R
AU  - Rucker,JJ
AU  - Hoare,J
AU  - Sodergren,MH
DO  - 10.1080/17474124.2022.2161046
EP  - 98
PY  - 2022///
SN  - 1747-4124
SP  - 85
TI  - The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry
T2  - Expert Review of Gastroenterology and Hepatology
UR  - http://dx.doi.org/10.1080/17474124.2022.2161046
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000903761000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.tandfonline.com/doi/full/10.1080/17474124.2022.2161046
UR  - http://hdl.handle.net/10044/1/101578
VL  - 17
ER  -
Download